News & Events about Madrigal Pharmaceuticals Inc.
Fool.com Headlines
1month ago
Two key tailwinds fueled a surge in the biotech's share price this week.Shares of clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) rose by a noteworthy 20% over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. The ...
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) have received a consensus recommendation of Moderate Buy from the fourteen research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has ...
Globe Newswire
3 months ago
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in the first half of 2023Madrigal reports year end cash, cash equivalents and marketable securities of $358.8M CONSHOHOCKEN, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- ...
Globe Newswire
3 months ago
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in three upcoming investor ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL Get Rating) Director Richard S. Levy sold 22,489 shares of the businesss stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $293.15, for a total transaction of $6,592,650.35. Following ...